Apellis Pharmaceuticals/ US03753U1060 /
| 6/18/2024 9:59:59 PM | Chg. -0.29 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 40.07USD | -0.71% | 24,663 Turnover: 995,344.71 |
-Bid Size: - | -Ask Size: - | 41.12 | 39.58 |
GlobeNewswire
6/10
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in...
GlobeNewswire
6/5
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare C...
GlobeNewswire
5/24
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and ...
GlobeNewswire
5/16
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnso...
GlobeNewswire
5/14
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire
5/6
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Confere...
GlobeNewswire
5/1
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology ...
GlobeNewswire
4/26
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by Europe...
GlobeNewswire
4/23
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financ...
GlobeNewswire
4/4
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4/1
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Confer...
GlobeNewswire
3/19
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnso...
GlobeNewswire
3/15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
3/11
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
GlobeNewswire
3/7
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights ...
GlobeNewswire
3/6
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3/5
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Di...
GlobeNewswire
3/4
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Offic...
GlobeNewswire
2/27
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
2/20
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and ...
GlobeNewswire
2/6
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
